Recent Translated Articles from The Oncologist


Volume 22, Number 9, September 2017


Clinical Trial Results

一项在携带KRAS突变的既往经治局部晚期或转移性癌症患者中评价Cobimetinib和Duligotuzumab的安全性、耐受性和药代动力学的Ib期剂量递增研究
A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H. Lieu, Manuel Hidalgo, Jordan D. Berlin, Andrew H. Ko, Andres Cervantes, Patricia LoRusso, David E. Gerber, J. Paul Eder, S. Gail Eckhardt, Amy V. Kapp, Amy Tsuhako, Bruce McCall, Andrea Pirzkall, Anne Uyei, Josep Tabernero
The Oncologist 2017; 22:1024-e89; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0175

IV期黑色素瘤患者中伴或不伴射频消融或冷冻消融的内源性热休克蛋白诱导
Endogenous Heat‐Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
Evidio Domingo‐Musibay, James M. Heun, Wendy K. Nevala, Matthew Callstrom, Thomas Atwell, Evanthia Galanis, Lori A. Erickson, Svetomir N. Markovic
The Oncologist 2017; 22:1026-e93; first published on July 5, 2017; doi:10.1634/theoncologist.2017-0060

Breast Cancer

靶向三阴性乳腺癌的分子亚型:理解分子亚型的多样性以在乳腺癌领域获得进展
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Clinton Yam, Sendurai A. Mani, Stacy L. Moulder
The Oncologist 2017; 22:1086-1093; first published on May 30, 2017; doi:10.1634/theoncologist.2017-0095

Palbociclib联合氟维司群治疗既往内分泌治疗后疾病进展的绝经前晚期乳腺癌女性:PALOMA-3的结果
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results
Sibylle Loibl, Nicholas C. Turner, Jungsil Ro, Massimo Cristofanilli, Hiroji Iwata, Seock‐Ah Im, Norikazu Masuda, Sherene Loi, Fabrice André, Nadia Harbeck, Sunil Verma, Elizabeth Folkerd, Kathy Puyana Theall, Justin Hoffman, Ke Zhang, Cynthia Huang Bartlett, Mitchell Dowsett
The Oncologist 2017; 22:1028-1038; first published on June 26, 2017; doi:10.1634/theoncologist.2017-0072

细胞周期蛋白依赖性激酶4/6抑制剂治疗乳腺癌的潜在毒性的临床管理以及与该药物相关的药物相互作用:实际考量和建议
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring, Mark L. Zangardi, Beverly Moy, Aditya Bardia
The Oncologist 2017; 22:1039-1048; first published on July 13, 2017; doi:10.1634/theoncologist.2017-0142

Hepatobiliary

肝胆多学科专家组评估对结直肠癌肝转移患者的影响:一项基于人群的研究
The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population‐Based Study
Jennie Engstrand, Nikolaos Kartalis, Cecilia Strömberg, Mats Broberg, Anna Stillström, Tobias Lekberg, Eduard Jonas, Jacob Freedman, Henrik Nilsson
The Oncologist 2017; 22:1067-1074; first published on May 26, 2017; doi:10.1634/theoncologist.2017-0028

Lung Cancer

吉非替尼一线治疗表皮生长因子受体(EGFR)突变阳性的晚期非小细胞肺癌患者的总生存期预后因素的真实世界数据
Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib
Zong‐Han Yao, Wei‐Yu Liao, Chao‐Chi Ho, Kuan‐Yu Chen, Jin‐Yuan Shih, Jin‐Shing Chen, Zhong‐Zhe Lin, Chia‐Chi Lin, James Chih‐Hsin Yang, Chong‐Jen Yu
The Oncologist 2017; 22:1075-1083; first published on May 15, 2017; doi:10.1634/theoncologist.2016-0331

Symptom Management and Supportive Care

多维状态马尔可夫模型检验终末期癌症患者在生命最后6个月中预后意识的转变
Transitions in Prognostic Awareness Among Terminally Ill Cancer Patients in Their Last 6 Months of Life Examined by Multi‐State Markov Modeling
Chen Hsiu Chen, Fur‐Hsing Wen, Ming‐Mo Hou, Chia‐Hsun Hsieh, Wen‐Chi Chou, Jen‐Shi Chen, Wen‐Cheng Chang, Siew Tzuh Tang
The Oncologist 2017; 22:1135-1142; first published on July 6, 2017; doi:10.1634/theoncologist.2017-0068